Overview A Multicenter Assessment of ALD403 in Frequent Episodic Migraine Status: Completed Trial end date: 2017-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs. Phase: Phase 3 Details Lead Sponsor: Alder Biopharmaceuticals, Inc.